BioCentury | Feb 2, 2018
Clinical News

Takeda, Zinfandel's AD test fails to deliver

...AD within five years. The algorithm has three components: apolipoprotein E (APOE) genotype, translocase of outer mitochondrial membrane 40 homolog (TOMM40; TOM40...
...TOMM40; TOM40) genotype and age. Takeda has exclusive, worldwide rights to develop and commercialize Zinfandel’s TOMM40...
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...metabolic indications Preclinical Undisclosed Undisclosed Jan. 2011 Zinfandel Pharmaceuticals Inc. Assay to measure translocase of outer mitochondrial membrane 40 homolog (TOMM40; TOM40...
BioCentury | Jan 25, 2018
Clinical News

Takeda, Zinfandel’s AD test fails to deliver

...AD within five years. The algorithm has three components: apolipoprotein E (APOE) genotype, translocase of outer mitochondrial membrane 40 homolog (TOMM40; TOM40...
...TOMM40; TOM40) genotype and age. Takeda has exclusive, worldwide rights to develop and commercialize Zinfandel’s TOMM40...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...algorithm that predicts risk based on the presence of apolipoprotein E (APOE) and translocase of outer mitochondrial membrane 40 homolog (TOMM40; TOM40...
BioCentury | Feb 22, 2016
Clinical News

Actos pioglitazone: Completed Phase III enrollment

...within 5 years. It has 3 components: apolipoprotein E (APOE) genotype, translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40...
...Actos for Type II diabetes. Takeda has exclusive, worldwide rights to develop and commercialize Zinfandel’s TOMM40...
BioCentury | Sep 16, 2013
Clinical News

Biomarker risk assignment algorithm: Phase III started

...for Type II diabetes. The genetic-based biomarker risk assignment algorithm is based on APOE and TOMM40...
...Takeda exclusive, worldwide rights to develop and commercialize an assay to detect variants of the TOMM40...
...APOE) ; Translocase of outer mitochondrial membrane 40 homolog (TOMM40) (TOM40) Description: Genetics-based biomarker risk assignment algorithm based on APOE and TOMM40...
BioCentury | Sep 16, 2013
Clinical News

Actos pioglitazone: Phase III started

...biomarker risk assignment algorithm is based on apolipoprotein E (APOE) and translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40...
...Takeda exclusive, worldwide rights to develop and commercialize an assay to detect variants of the TOMM40...
BioCentury | Aug 5, 2013
Clinical News

Biomarker risk assignment algorithm diagnostic data

...Takeda exclusive, worldwide rights to develop and commercialize an assay to detect variants of the TOMM40...
...APOE) ; Translocase of outer mitochondrial membrane 40 homolog (TOMM40) (TOM40) Description: Genetics-based biomarker risk assignment algorithm based on APOE and TOMM40...
BioCentury | Jan 17, 2011
Company News

Zinfandel Pharmaceuticals, Takeda deal

...the translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40 ) gene. The companies will attempt to prospectively validate TOMM40...
BioCentury | Jan 12, 2011
Company News

Takeda, Zinfandel in AD biomarker deal

...the translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40 ) gene. The companies will attempt to prospectively validate TOMM40...
Items per page:
1 - 10 of 13